Follow-up validation of the pre-clinically defined surface fingerprint in a cohort of PCa patient samples resulted in a 6-molecule surface fingerprint composed of EpCAM, CD9, CD44, CD59, CD95, and SSEA-4. Here, EPCAM is linked to posterior cortical atrophy.